Rajiv Agarwal

机构：Brigham and Women's Hospital, Harvard University, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis · ORCID：0000-0001-8355-7100

发表论文 440 篇 · 总被引 26999 次 · h-index 81

代表论文

• Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025 · Diabetes Care · 被引 13)
• Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both (2025 · Journal of the American College of Cardiology · 被引 6)
• Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia (2025 · Clinical Journal of the American Society of Nephrology · 被引 6)
• Effect of Finerenone on Morbidity and Mortality in CKD (2025 · Journal of the American Society of Nephrology · 被引 5)
• Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both (2025 · Journal of the American Society of Nephrology · 被引 3)
• Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia (2025 · Clinical Journal of the American Society of Nephrology · 被引 3)